Literature DB >> 18395862

Is FOXP3 a bona fide marker for human regulatory T cells?

Maria-Grazia Roncarolo1, Silvia Gregori.   

Abstract

FOXP3 is a specific marker for naturally occurring regulatory T cells (nTreg). FOXP3 expression is correlated with development and function of nTreg. Recent evidence suggests that, upon activation, human effector T (Teff) cells and type 1 regulatory T (Tr1) cells can express FOXP3, albeit transiently. While the role of transient FOXP3 expression in Teff cells is poorly understood, it is becoming clear that it does not correlate with suppressor function. Furthermore, FOXP3-independent mechanisms, mediated by IL-10, contribute to the induction and suppressor functions of Tr1 cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18395862     DOI: 10.1002/eji.200838168

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  69 in total

1.  Neutralizing IL-6 reduces human arterial allograft rejection by allowing emergence of CD161+ CD4+ regulatory T cells.

Authors:  Birgit Fogal; Tai Yi; Chen Wang; Deepak A Rao; Amir Lebastchi; Sanjay Kulkarni; George Tellides; Jordan S Pober
Journal:  J Immunol       Date:  2011-11-14       Impact factor: 5.422

Review 2.  Regulatory T-cell therapy for inflammatory bowel disease: more questions than answers.

Authors:  Megan E Himmel; Yu Yao; Paul C Orban; Theodore S Steiner; Megan K Levings
Journal:  Immunology       Date:  2012-06       Impact factor: 7.397

3.  Perspectives on Regulatory T Cell Therapies.

Authors:  Michael Probst-Kepper; Andrea Kröger; Henk S P Garritsen; Jan Buer
Journal:  Transfus Med Hemother       Date:  2009-09-10       Impact factor: 3.747

4.  Reduced levels of both circulating CD4+ CD25+ CD127(low/neg) and CD4+ CD8(neg) invariant natural killer regulatory T cells in stable heart transplant recipients.

Authors:  M Chen; M Mohtize; M-F Matteï; J-P Villemot; C Kohler; G C Faure; M C Béné; M de Carvalho Bittencourt
Journal:  Clin Exp Immunol       Date:  2010-10-29       Impact factor: 4.330

5.  Comprehensive analysis of frequency and phenotype of T regulatory cells in HIV infection: CD39 expression of FoxP3+ T regulatory cells correlates with progressive disease.

Authors:  Julian Schulze Zur Wiesch; Adriana Thomssen; Philip Hartjen; Ilona Tóth; Clara Lehmann; Dirk Meyer-Olson; Kristina Colberg; Sebastian Frerk; Dalia Babikir; Stefan Schmiedel; Olaf Degen; Stefan Mauss; Jürgen Rockstroh; Schlomo Staszewski; Pavel Khaykin; Alexander Strasak; Ansgar W Lohse; Gerd Fätkenheuer; Joachim Hauber; Jan van Lunzen
Journal:  J Virol       Date:  2010-11-03       Impact factor: 5.103

Review 6.  Inhibitory CD8+ T cells in autoimmune disease.

Authors:  Masakatsu Suzuki; Christine Konya; Jörg J Goronzy; Cornelia M Weyand
Journal:  Hum Immunol       Date:  2008-09-21       Impact factor: 2.850

Review 7.  Induced and natural regulatory T cells in human cancer.

Authors:  Theresa L Whiteside; Patrick Schuler; Bastian Schilling
Journal:  Expert Opin Biol Ther       Date:  2012-07-31       Impact factor: 4.388

8.  Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors.

Authors:  Katy Milne; Martin Köbel; Steven E Kalloger; Rebecca O Barnes; Dongxia Gao; C Blake Gilks; Peter H Watson; Brad H Nelson
Journal:  PLoS One       Date:  2009-07-29       Impact factor: 3.240

9.  IL-10 is critically involved in mycobacterial HSP70 induced suppression of proteoglycan-induced arthritis.

Authors:  Lotte Wieten; Suzanne E Berlo; Corlinda B Ten Brink; Peter J van Kooten; Mahavir Singh; Ruurd van der Zee; Tibor T Glant; Femke Broere; Willem van Eden
Journal:  PLoS One       Date:  2009-01-14       Impact factor: 3.240

10.  Human regulatory T cell suppressive function is independent of apoptosis induction in activated effector T cells.

Authors:  Yvonne Vercoulen; Ellen J Wehrens; Nienke H van Teijlingen; Wilco de Jager; Jeffrey M Beekman; Berent J Prakken
Journal:  PLoS One       Date:  2009-09-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.